Viatris (LTS:0A5V) Investments And Advances : $1,477 Mil (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Viatris Investments And Advances?

Viatris's Investments And Advances for the quarter that ended in Sep. 2024 was $1,477 Mil.

Viatris's quarterly Investments And Advances increased from Mar. 2024 ($1,189 Mil) to Jun. 2024 ($1,438 Mil) and increased from Jun. 2024 ($1,438 Mil) to Sep. 2024 ($1,477 Mil).

Viatris's annual Investments And Advances increased from Dec. 2021 ($81 Mil) to Dec. 2022 ($1,091 Mil) and increased from Dec. 2022 ($1,091 Mil) to Dec. 2023 ($1,142 Mil).

Viatris Investments And Advances Historical Data

The historical data trend for Viatris's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Investments And Advances Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Investments And Advances

Get a 7-Day Free Trial

92.20

47.90

81.40

1,091.40

1,142.00

Viatris Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Investments And Advances	Get a 7-Day Free Trial															1,213.70	1,142.00	1,188.90	1,437.70	1,477.10

Viatris Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Viatris Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (LTS:0A5V) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy VIA:Germany VIA:Germany VIA:Germany VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris Headlines

No Headlines